Salvage Treatment for Persistent Methicillin‐Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high mortality rates, but no treatment strategy has yet been established. We performed this study to evaluate the efficacy of linezolid with or without carbapenem in salvage treatment for persistent MRSA bacteremia. METHODS: All adult patients with persistent MRSA bacteremia for 7 days from January 2006 through March 2008 who were treated at Seoul National University Hospital were studied. The results of linezolid salvage therapy with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides or rifampicin. RESULTS: Thirty-five patients with persistent MRSA bacteremia were studied. The early microbiological response (ie, negative results for follow-up blood culture within 72 hours) was significantly higher in the linezolid-based salvage therapy group than the comparison group (75% vs 17%; P =.006). Adding aminoglycosides or rifampicin to vancomycin was not successful in treating any of the patients, whereas linezolid-based therapy gave an 88% salvage success rate P =.001). The S. aureus-related mortality rate was lower for patients treated with a linezolid salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; P =.030). CONCLUSIONS: Linezolid-based salvage therapy effectively eradicated S. aureus from the blood for patients with persistent MRSA bacteremia. The salvage success rate was higher for linezolid therapy than for vancomycin-based combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Linezolid was reported to be effective in the treatment of persistent MRSA bacteremia, 172 but this study had important study design weaknesses.173”
Citations
Cites
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,005
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“teremia in the United States [2].”
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Clinical Identifiers of Complicated Staphylococcus aureus Bacteremia
Fowler, V. G., Olsen, M. K., Corey, G. R., Woods, C. W., Cabell, C. H., Reller, L. B., Cheng, A. C., Dudley, T., & Oddone, E. Z. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.17.2066 · Cited by 652
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Fowler, Jr., Sakoulas, G., McIntyre, L. M., Meka, V. G., Arbeit, R. D., Cabell, C. H., Stryjewski, M. E., Eliopoulos, G. M., Reller, L. B., Corey, G. R., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423145 · Cited by 351
Jones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254
Howden, B. P., Johnson, P. D. R., Ward, P. B., Stinear, T. P., & Davies, J. K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00422-06 · Cited by 224
Cited by
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
“Levine et al,45 1991 (openlabel RCT) Moderate 42 MRSA endocarditis (median [range] age of 32 [23-61] y); treatment with vancomycin alone (1 g every 12 h; n = 22) vs vancomycin (1 g every 12 h) plus rifampin (600 mg/d) (n = 20) Duration of bacteremia Median duration of 9 d for bacteremia for all patients; 7 (95% CI, 5…”
Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?
Thwaites, G. E., & Gant, V. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2508 · Cited by 320
Recent Developments in Methicillin-Resistant Staphylococcus aureus (MRSA) Treatment: A Review
Nandhini, P., Kumar, P., Mickymaray, S., Alothaim, A. S., Somasundaram, J., & Rajan, M. (2022) · Antibiotics · doi:10.3390/antibiotics11050606 · Cited by 289
Clinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
Rifampin Combination Therapy for Nonmycobacterial Infections
Forrest, G. N., & Tamura, K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-09 · Cited by 242
Moellering, R. C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr437 · Cited by 236
Kaushik, A., Kest, H., Sood, M., Steussy, B., Thieman, C., & Gupta, S. (2024) · Pathogens · doi:10.3390/pathogens13010076 · Cited by 199
“Other combinations that have shown promise include ceftaroline alone or combined with trimethoprim– sulfamethoxazole or vancomycin [69,70], combinations of linezolid with a carbapenem, or telavancin with ceftaroline or rifampin [71,72].”
Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis
Pea, F., Furlanut, M., Cojutti, P., Cristini, F., Zamparini, E., Franceschi, L., & Viale, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00177-10 · Cited by 198
Kalil, A. C., Van Schooneveld, T. C., Fey, P. D., & Rupp, M. E. (2014) · JAMA · doi:10.1001/jama.2014.6364 · Cited by 172
Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Choo, E. J., & Chambers, H. F. (2016) · Infection & Chemotherapy · doi:10.3947/ic.2016.48.4.267 · Cited by 168
“cleared within 72 hours in only 2 (17%) [21].”
BackgroundChong, Y. P., Moon, S. M., Bang, K. M., Park, H. J., Park, S.-Y., Kim, M., Park, K., Kim, S., Lee, S., Choi, S., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01021-12 · Cited by 134
Self-citationNguyen, H. M., & Graber, C. J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp377 · Cited by 132
Future Challenges And Treatment Of Staphylococcus Aureus Bacteremia With Emphasis On MRSA
Rasmussen, R. V., Fowler, V. G., Skov, R. L., & Bruun, N. E. (2010) · Future Microbiology · doi:10.2217/fmb.10.155 · Cited by 144
“Although one observational Korean study suggested that linezolid had utility in the setting of persistent MRSA bacteremia, rates of myelosuppression (as indicated by thrombocytopenia) were significantly higher in the linezolid recipients [125].”
Purrello, S., Garau, J., Giamarellos‐Bourboulis, E. J., Mazzei, T., Pea, F., Soriano, À., & Stefani, S. (2016) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2016.07.010 · Cited by 128
“Linezolid has been compared with vancomycin for SAB in several case series and observational cohorts [95–99].”
BackgroundFraimow, H. S., & Tsigrelis, C. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.002 · Cited by 106
“are reports on the use of linezolid plus carbapenems for refractory MRSA bacteremia.(71) Combinations of daptomycin and gentamicin or rifampin demonstrate variable effects in vitro and in animal models, and clinical data are lacking.”
BackgroundClinical update on linezolid in the treatment of Gram-positive bacterial infections
Gould, K. (2012) · Infection and Drug Resistance · doi:10.2147/idr.s25890 · Cited by 98
“A meta-analysis by Beibei et al looked at results from 271 evaluable patients in three RCTs where linezolid was used to treat patients with bacteremia and found no statistically significant difference in treatment success between those receiving linezolid or vancomycin 93 Jang et al compared salvage treatment with lin…”
Treatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia
Lewis, P. O., Heil, E. L., Covert, K. L., & Cluck, D. B. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12743 · Cited by 91
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Holmes, N. E., Tong, S. Y. C., Davis, J. S., & van Hal, S. J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1397040 · Cited by 93
When sepsis persists: a review of MRSA bacteraemia salvage therapy
Kullar, R., Sakoulas, G., Deresinski, S. C., & van Hal, S. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv368 · Cited by 75
Kelesidis, T., Humphries, R. M., Ward, K. W., Lewinski, M. A., & Yang, O. O. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.07.001 · Cited by 58
“aureus from the blood for patients with persistent MRSA bacteremia (Jang et al., 2009).”
BackgroundResultInfluentialPark, K., Shin, J. H., Lee, S. Y., Kim, S. H., Jang, M. O., Kang, S., Jung, S., Chung, E., Ko, K. S., & Jang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065026 · Cited by 56
“Mortality was defined as Acinetobacter-related in the absence of another definite cause of death [18].”
Self-citationKullar, R., McKinnell, J. A., & Sakoulas, G. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu583 · Cited by 53
“Jang et al [22] evaluated linezolid salvage therapy with or without ertapenem versus salvage therapy with vancomycin”
Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021
Демин, А. А., Kobalava, Z. D., Skopin, I. I., Tyurin, P. V., Boytsov, S. A., Golukhova, E. Z., Гордеев, М. Л., Gudymovich, V. D., Demchenko, E. A., Дробышева, В. П., et al. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5233 · Cited by 69
Dryden, M., Andrašević, A. T., Bassetti, M., Bouza, E., Chastre, J. E., Cornaglia, G., Esposito, S., French, G. L., Giamarellou, H., Gyssens, I. C., et al. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03135.x · Cited by 57
“Linezolid in combination with rifampin and/or fusidic acid [97] or carbapenems [98] has been used as salvage therapy for difficult cases.”
MethodLin, S.-H., Liao, W.-H., Lai, C.-C., Liao, C.-H., Tan, C.-K., Wang, C.-Y., Huang, Y.-T., & Hsueh, P.-R. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq188 · Cited by 48
Bloem, A., Bax, H. I., Yusuf, E., & Verkaik, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081743 · Cited by 49
“In the case of persistent MRSA bacteremia (≥7 days), linezolid proved to be statistically more effective than vancomycin in terms of early microbiological response, success rate, and mortality rate [106].”
BackgroundMethicillin-resistant Staphylococcus aureus antibiotic resistance and virulence
Xia, J., Gao, J., Kokudo, N., Hasegawa, K., & Tang, W. (2013) · BioScience Trends · doi:10.5582/bst.2013.v7.3.113 · Cited by 57
“bacteraemia and endocarditis with both vancomycin and rifampicin (41-43).”
Jang, M.-O., Jang, H., Kim, U. J., Ahn, J. H., Kang, S., Jung, S.-I., Shin, H., & Park, K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01996-13 · Cited by 43
“Mortality was defined as scrub typhus related if there was no other definite cause of death (15).”
BackgroundSelf-citationKang, C. K., Kim, E. S., Song, K., Kim, T. S., Kim, K.-H., Kim, C.-J., Kim, C.-J., Choe, P. G., Bang, J.-H., Park, K. U., et al. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-365 · Cited by 41
Self-citationMultiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia
Chen, C.-J., Huang, Y.-C., & Chiu, C.-H. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv225 · Cited by 41
Bacteremia due to Methicillin-Resistant Staphylococcus aureus
Holubar, M. K., Meng, L., & Deresinski, S. C. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.009 · Cited by 46
Song, K., Kim, E. S., Sin, H.-Y., Park, K., Jung, S., Yoon, N.-R., Kim, D., Lee, C. S., Jang, H., Park, Y., et al. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-581 · Cited by 39
“A primary diagnosis was made on the basis of the clinical, radiological, and microbiological information [13].”
BackgroundSelf-citationLee, Y., Chen, P., Wang, J., & Chang, S. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0305-y · Cited by 43
Garzoni, C., & Vergidis, P. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12098 · Cited by 41
Park, H. J., Kim, S., Kim, M.-J., Lee, Y., Park, S.-Y., Moon, S. M., Park, K., Chong, Y. P., Lee, S., Choi, S., et al. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.08.007 · Cited by 41
Self-citationPharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Gudiol, C., Cuervo, G., Shaw, E., Pujol, M., & Carratalà, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1403585 · Cited by 63
“apy for persistent MRSAB [98,99] or refractory MRSA IE”
BackgroundPereira, M. R., Rana, M. M., & Practice, T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13611 · Cited by 35
Bacteremia due to Methicillin-Resistant Staphylococcus aureus
Holubar, M. K., Meng, L., Alegria, W., & Deresinski, S. C. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.04.003 · Cited by 34
Hornak, J. P., Anjum, S. H., & Reynoso, D. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119886504 · Cited by 39
Joson, J., Grover, C. A., Downer, C., Pujar, T., & Heidari, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr234 · Cited by 31
Invasive community-associated MRSA infections: epidemiology and antimicrobial management
Pichereau, S., & Rose, W. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511614 · Cited by 31
“However, a recent report described clearance of bacteremia in 14 of 16 cases in patients with linezolid-based therapy (linezolid alone in seven cases and linezolid plus a carbapenem in nine cases) [43].”
BackgroundKim, K.-H., Sung, J. Y., Choi, Y. J., Choi, S., Ahn, S., Ji, E., Kim, M., Kim, C.-J., Song, K., Choe, P. G., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05641-z · Cited by 29
Self-citationJackson, J. K., Leung, F., Duncan, C. P., Mugabe, C., & Burt, H. M. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0015-5 · Cited by 29
“Linezolid has been shown to be effective in the treatment of a wide range of drug-resistant infections and to be well suited to encapsulation in bone cement [5, 19, 34].”
BackgroundXu-hong, Y., Falagas, M. E., Dong, W., Karageorgopoulos, D. E., De-feng, L., & Wang, R. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.5 · Cited by 29
Tremblay, S., Lau, T. T. Y., & Ensom, M. H. H. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r726 · Cited by 31
El catéter periférico: el gran olvidado de la infección nosocomial
Capdevila, J. A. (2013) · Revista española de quimioterapia. Suplemento · Cited by 57
Jang, H., Choi, O.-J., Kim, G.-S., Jang, M.-O., Kang, S., Jung, S., Shin, J. H., Chun, B. J., & Park, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099192 · Cited by 27
“Methicillin-resistant Staphylococcus aureus (MRSA) is a major human pathogen causing a wide range of both community-onset and nosocomial infections [1–3], and the identification of MRSA carriage is therefore an important tool for the control and prevention of these infections.”
BackgroundSelf-citationLee, S. Y., Shin, J. H., Park, K. H., Kim, J. H., Shin, M., Suh, S., Ryang, D. W., & Kim, S. H. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02868-13 · Cited by 25
Self-citationRole of linezolid combination therapy for serious infections: review of the current evidence
Chen, H., Du, Y. Z., Xia, Q., Li, Y., Song, S., & Huang, X. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03801-x · Cited by 35
Wang, J., Lai, C.-H., Lin, H.-H., Chen, W.-F., Shih, Y.-C., & Hung, C. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.07.010 · Cited by 26
Small-Colony Variants in Persistent and Recurrent Staphylococcus aureus Bacteremia
Kim, K.-H., Kang, Y. M., Han, W. D., Park, K. U., Park, K., Yoo, J. I., Lee, D., Park, C., Song, K., Kim, E. S., et al. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0262 · Cited by 28
Self-citationJang, H., Kang, S., Choi, S., Park, K., Shin, J. H., Choy, H. E., Jung, S., & Kim, H. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049136 · Cited by 19
Self-citationBaxi, S. M., Clemenzi-Allen, A., Gahbauer, A., Deck, D. H., Imp, B. M., Vittinghoff, E., Chambers, H. F. “., & Doernberg, S. B. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00658-16 · Cited by 18
Bakthavatchalam, Y. D., Rao, S. V., Isaac, B. T. J., Abi Manesh, S., Nambi, S., Swaminathan, S., Nagvekar, V., Nangia, V., John, P. V., & Veeraraghavan, B. (2019) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_20_34 · Cited by 21
Burnham, J. P., Burnham, C. D., Warren, D. K., & Kollef, M. H. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-16 · Cited by 16
“Linezolid as a salvage therapy for patients with MRSA infections failing vancomycin therapy has shown success rates superior to and mortality lower than those seen with vancomycin combination therapy, albeit in a cohort of only 35 patients (34).”
ResultWang, B., Jessamine, P. G., Desjardins, M., Toye, B., & Ramotar, K. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.09.014 · Cited by 16
“Previous studies have demonstrated that MRSA bloodstream infections have higher mortality and morbidity (Cosgrove et al., 2003; Cosgrove and Fowler, 2008; Jang et al., 2009).”
ResultRapti, V., Giannitsioti, E., Spernovasilis, N. A., Magiorakos, A.-P., & Poulakou, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062087 · Cited by 19
“Alternative regimens include fosfomycin plus imipenem [59], quinupristin–dalfopristin with or without beta-lactams [60], beta-lactams plus linezolid [61], high doses of trimethoprim/sulfamethoxazole plus clindamycin [62,63], and beta-lactams plus vancomycin [64].”
Linezolid for infective endocarditis: A structured approach based on a national database experience
Muñóz, P., de la Villa, S., Martínez‐Sellés, M., Goenaga, M. Á., Reviejo, K., Revillas, F. A. D. L., García-Cuello, L., Hidalgo-Tenorio, C., Esteban, Á. R., Antorrena, I., et al. (2021) · Medicine · doi:10.1097/md.0000000000027597 · Cited by 12
Seah, J., Lye, D. C., Ng, T. M., Krishnan, P., Choudhury, S., & Teng, C. B. (2013) · Virulence · doi:10.4161/viru.26909 · Cited by 13
“In a Korean study, adding aminoglycoside and/ or rifampicin did not improve outcome, whereas switching from vancomycin to linezolid (with or without a carbapenem) resulted in improved microbiologic clearance and lower infection-related mortality.(19) Another study suggested that switching to linezolid or combination t…”
BackgroundLee, Y., Chong, Y. P., Kim, M. J., Eom, Y., Kim, E. S., Kim, M., Park, K., Kim, S., Lee, S., Choi, S., et al. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03795-6 · Cited by 10
Self-citationYavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Lee, J. Y. H., & Howden, B. P. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1041924 · Cited by 9
“As described above, successful use of linezolid-based salvage has been implemented in the setting of failing vancomycin therapy with persistent MRSA bacteremia [80].”
Backgroundthe Korea INfectious Diseases (KIND) study group, Kang, C. K., Kwak, Y. G., Park, Y., Song, K., Kim, E. S., Jung, S., Park, K., Park, W. B., Kim, N. J., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3226-6 · Cited by 9
Self-citationMinotti, C., Zuccon, I., Priante, E., Bonadies, L., Chiara, C. D., Donà, D., Baraldi, E., & Costenaro, P. (2022) · Children · doi:10.3390/children9040457 · Cited by 9
“Linezolid was not considered because of its bacteriostatic effect and the risk of myelosuppression from its prolonged course in an extremely preterm, immunosuppressed infant [7].”
BackgroundHagiya, H., Terasaka, T., Kimura, K., Satou, A., Asano, K., Waseda, K., Hanayama, Y., & Otsuka, F. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.2711 · Cited by 7
“reported that salvage therapy with LZD is superior to that of VCM for eradicating persistent MRSA bacteremia (31).”
BackgroundEarly appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs
Grossi, P. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70563-1 · Cited by 7
“aureus from the blood within 72 h in patients with persistent MRSA bacteraemia [28].”
BackgroundBourkia, M., Charles, L., Lambotte, O., Orostegui-Giron, L., Goujard, C., & Ghosn, J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr227 · Cited by 6
Kumar, A., & Kethireddy, S. (2010) · Yearbook of Critical Care Medicine · doi:10.1016/s0734-3299(09)79332-3 · Cited by 6
New therapeutic approach for the treatment for staphylococcal bacteremia and sepsis
Борисович, Б. В. (2014) · Epidemiology and Infectious Diseases · doi:10.17816/eid40824 · Cited by 5
Kim, H. K., Choi, S.-M., Kang, G., Park, K. H., Lee, D., Park, W. B., Rhee, S., Lee, S., Jung, S., & Jang, H. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.4.301 · Cited by 5
“aureus (MRSA) infections.(4,5) Several studies have suggested that both MRSA strains exhibiting increased vancomycin minimum inhibitory Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea”
BackgroundSelf-citationTattevin, P., Uhel, F., & Fily, F. (2009) · Clinical Infectious Diseases · doi:10.1086/648500 · Cited by 4
“Indeed, as the introduction of linezolid was treated as a time-invariant factor in their analysis, the authors did not take into account the fact that patients who received linezolid may be different from those who did not, simply by virtue of having survived until the date of treatment alteration [2].”
BackgroundTaddese, D., Abdurahaman, M., Debelo, M., Shumi, E., Ayana, G. U., Kefyalew, D., Melaku, M., Kebeta, T., & Abafaji, G. (2025) · Discover Food · doi:10.1007/s44187-025-00300-1 · Cited by 8
Sklyar, T. V., Lavrentievа, K. V., Gavrilyuk, V. G., Kurahina, N. V., Vereshchaha, M. O., & Lykholat, O. A. (2018) · Regulatory Mechanisms in Biosystems · doi:10.15421/021841 · Cited by 4
“…methicillin-resistant strains of S. aureus, characterrized by multiple resistance to antibiotics, including the preparations of choice, is becoming increasingly relevant (Jang et al., 2009; Marimuthu et Harbarth, 2014; Lawes et al., 2015; van Kleef et al., 2017; Hamdan-Partida et al., 2018).”
BackgroundAnti-Alpha-Toxin Antibody Responses and Clinical Outcomes of Staphylococcus aureus Bacteremia
Kim, K.-H., Choi, Y. J., Kwon, K., Park, J. S., Park, K. U., Moon, S. M., Song, K., Kim, E. S., Park, W. B., & Kim, H. B. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e129 · Cited by 6
Self-citationMultidrug-Resistant Gram-Positive Bacterial Infections
Jung, Y., & Kim, H. B. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.88.5.487 · Cited by 5
“Vancomycin 치료 실패 때 구제요법으로 vancomycin에 다른 약제를 추가하는 것과 linezolid를 기반으로 하는 치료로 변경하는 것을 비교 하였을 때 후자에서 30일 사망률이 낮다는 보고도 있으나 [69] 다른 연구에서는 linezolid와 glycopeptide 치료 성적의 차 이가 없었고[70], 좌측 심내막염에서 linezolid의 성적이 나쁜 것으로 알려져 있어 주의가 필요하다[6,69,71].”
Self-citationStaphylococcus aureus Bacteremia and Native Valve Endocarditis: The Role of Antimicrobial Therapy
Karchmer, A. W. (2012) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e31824a8bcb · Cited by 4
Policarpo, S. N., Duro, R. P., Rocha-Pereira, N., & Santos, L. (2024) · Cureus · doi:10.7759/cureus.54134 · Cited by 3
Shaddix, G., Patel, K., Simmons, M., & Burner, K. (2019) · Case Reports in Infectious Diseases · doi:10.1155/2019/5623978 · Cited by 2
Howden, B. P. (2010) · CRC Press eBooks · doi:10.1201/b13787-81 · Cited by 2
Todd, J. K. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00174-3 · Cited by 3
Theuretzbacher, U. (2013) · Springer eBooks · doi:10.1007/978-0-387-75613-4_16 · Cited by 1
Kang, C. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.6.657 · Cited by 1
“independent predictors for persistent MRSA bacteremia, which are similar findings to those of previous studies [2-4].”
BackgroundResultShiba, M., Yanai, M., Maeda, H., & Shiono, M. (2015) · SAGE Open Medical Case Reports · doi:10.1177/2050313x15591314 · Cited by 1
Alsaeed, A., Wright, G. R., Deneer, H. G., Rubin, J. E., Sanche, S. E., & Blondeau, J. M. (2020) · Journal of Chemotherapy · doi:10.1080/1120009x.2020.1761191 · Cited by 1
Mitsutake, K., Shinya, N., Seki, M., Ohara, T., Uemura, K., Fukunaga, M., Sakai, J., Nagao, M., Sata, M., Hamada, Y., et al. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.02.027 · Cited by 1
Efficacy and Tolerability of Linezolid for Treatment of Infectious Spondylitis
Jung, J., Lee, E., Song, K., Choe, P. G., Park, W. B., Bang, J. H., Kim, E. S., Kim, H. B., Park, S., Kim, N. J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.5.464 · Cited by 1
Self-citationYoon, Y. K., Kim, C. H., Kim, H. C., Lee, J. H., Kim, J. Y., Park, D. W., Sohn, J. W., & Kim, M. J. (2010) · Infection and Chemotherapy · doi:10.3947/ic.2010.42.4.249 · Cited by 1
Self-citationPresent and Emerging Therapies for the Treatment of Drug-resistant Infections: Focus on Linezolid
Souli, M. (2010) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s1571
Kim, Y. S., Kim, J.-B., Lee, Y., Kim, S., Choi, S., Woo, J. H., & Kim, Y. S. (2012) · Korean Journal of Medicine · doi:10.3904/kjm.2012.82.4.512
“Glycopeptide계 항균제 치료에 실패한 지속적인 MRSA 균 혈증에 대한 치료에는 일반적으로 고용량 daptomycin (10 mg/ kg/day)의 사용이 추천되지만, 국내에는 현재 daptomycin이 도입되어 있지 않아 본 저자들은 linezolid를 구제요법으로 사용하였고, 추적 혈액배양 검사에서 균 음전되었다[2,10].”
Self-citationKim, S. B., Oh, D. H., Kim, Y. C., Kim, M. H., Song, J. E., Ahn, J. Y., Jeong, S. J., Goo, N. S., Kim, H. W., Han, S. H., et al. (2012) · Infection and Chemotherapy · doi:10.3947/ic.2012.44.5.403
Self-citationLee, K., Kim, H., Kim, J., Lee, G., Lee, H., Kim, H., Kim, D., Sohn, I. W., & Pai, H. (2010) · Infection and Chemotherapy · doi:10.3947/ic.2010.42.6.415
Self-citationSevere, non-bacteremic infections in ICU patients
Aguado, J. M., Torres, A., Muñóz, P., Soriano, À., Carratalà, J., Guirao, X., & Varó, E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70030-1
Kim, N., Kim, M., Jang, E. S., Kang, Y. M., Kim, G., Jang, H., Park, W. B., Kim, E.-C., Kim, N. J., & Oh, M. (2009) · Infection and Chemotherapy · doi:10.3947/ic.2009.41.6.371
Self-citationNouvelles associations dans le traitement des infections graves à cocci à Gram positif
Fernandez‐Gerlinger, M., & Mainardi, J. (2014) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2014.01.003 · Cited by 1
Staphylococcus aureus bacteraemia - Disease progression and prognosis
Forsblom, E. (2014) · Helda - University of Helsinki Institutional Repository
Metadata
- Authors
- Jang, H., Kim, S., Kim, K. H., Kim, C. J., Lee, S., Song, K., Jeon, J. H., Park, W. B., Kim, H. B., Park, S., Kim, N. J., Kim, E., Oh, M., & Choe, K. W.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Oh, Myoung‐don
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08
- Volume
- 49
- Issue
- 3
- Pages
- 395-401
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2170146384
- Cited by
- 113
- References
- 26
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 7 · 2019: 7 · 2018: 4 · 2017: 1 · 2016: 7 · 2015: 8 · 2014: 10 · 2013: 12 · 2012: 9
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- methicillin-resistant Staphylococcus aureus, linezolid, carbapenems, salvage therapy, vancomycin, aminoglycosides, rifampicin, combination antibiotic therapy, mortality, microbiological response
- MeSH terms
- Linezolid, Acetamides, Adolescent, Adult, Aged, Aged, 80 and over, Aminoglycosides, Anti-Bacterial Agents, Drug Therapy, Combination, Humans, Korea, Middle Aged, Staphylococcal Infections, Vancomycin, Carbapenems, Bacteremia, Salvage Therapy, Treatment Outcome, Oxazolidinones, Methicillin-Resistant Staphylococcus aureus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.